Conjugated estrogen/bazedoxifene (CE/BZA) therapy represents a new, progestin-free treatment in the management of postmenopausal health. CE/BZA pairs CE with the selective estrogen receptor modulator, BZA. The rationale for the development of CE/BZA was that BZA, acting primarily as a selective estrogen receptor degrader in uterine and breast tissue, would sufficiently inhibit the proliferative effects of CE on the endometrium. The absence of a progestin would reduce the incidence of uterine bleeding, breast pain and increased breast density associated with progestin-containing hormone therapy. CE/BZA has been evaluated in five multicenter, randomized, double-blind, placebo-controlled, and active-controlled Phase III trials known as the SMART trials. CE/BZA has been shown to maintain the established benefits of estrogen therapy for treatment of vasomotor symptoms and prevention of a loss in bone mineral density (bone mass), while minimizing certain estrogenic effects, particularly in the uterine endometrium and breast.
ArcherDF. Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms. Drugs Aging27(7), 533–544 (2012).
5.
Comprehensive clinical review of the topic.
6.
MaartensLWLeusinkGLKnottnerusJAClimacteric complaints in the community. Fam. Pract.18(2), 189–194 (2001).
7.
GoldEBSternfeldBKelseyJLRelation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40–55 years of age. Am. J. Epidemiol.152(5), 463–473 (2000).
RodstromKBengtssonCLissnerLA longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century. Menopause9(3), 156–161 (2002).
10.
KronenbergF. Hot flashes: epidemiology and physiology. Ann. NY Acad. Sci.592, 52–86 (1990).
11.
FreemanEWSherifK. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric10(3), 197–214 (2007).
12.
PolitiMCSchleinitzMDColNF. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J. Gen. Inten. Med.23(9), 1507–1513 (2008).
13.
McKinlaySMBrambillaDJPosnerJG. The normal menopause transition. Maturitas14(2), 103–115 (1992).
14.
UtianWH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual. Life Outcomes3, 47 (2005).
15.
LewisV. Undertreatment of menopausal symptoms and novel options for comprehensive management. Curr. Med. Res. Opin.25(11), 2689–2698 (2009).
16.
WhiteleyJWagnerJSBushmakenAKopenhaferLRacketaJ. The impact of severity of VMS on health status, resource use and productivity. Presented at: North American Menopause Society 22nd Annual Meeting.Washington, DC, USA, 21–24 September 2011.
17.
NIH. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann. Intern. Med.142(12), 1003–1013 (2005).
18.
MacLennanAHBroadbentJLLesterSMooreV. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst. Rev.4, CD002978 (2009).
19.
North American Menopause Society. The 2012 Hormone Therapy Position Statement of the North American Menopause Society. Menopause19(3), 257–271 (2012).
20.
North American Menopause Society guidelines on hormone replacement therapy.
21.
WattanakumtornkulSChichareonSGeaterACompliance with hormone replacement therapy at Songklanagarind Hospital. J. Obstet. Gynaecol. Res.29(8), 380–387 (2003).
22.
ManonaiJTheppisaiUSuchartwatnachaiCCompliance with hormone replacement therapy in Thai women. Maturitas44(5), 201–205 (2003).
23.
MirkinSNavarroFArcherDF. Hormone therapy and endometrial angiogenesis. Climacteric6(4), 273–277 (2003).
24.
Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA288(3), 321–333 (2002).
25.
Primary Women's Health Initiative publication.
26.
ChlebowskiRTHendrixSLLangerRDInfluence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA289(24), 3234–3253 (2003).
27.
Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women study. Lancet362(9382), 419–427 (2003).
28.
ChlebowskiRTAndersonGLGassMEstrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA304(15), 1684–1692 (2010).
29.
PitkinJ. Alternative and complementary therapies for the menopause. Menopause Int.18(1), 20–27 (2012).
30.
WahabMThompsonJAl-AzzawiF. Effect of different cyclical sequential progestins on endometrial vascularity in postmenopausal women compared with the natural cycle: a morphometric analysis. Hum. Reprod.15(10), 2075–2081 (2000).
31.
Lewis-WambiJSKimHCurpanRThe selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor a and cyclin D1. Mol. Pharmacol.80(4), 610–620 (2011).
32.
KommBSChinesAA. An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis. Maturitas71(3), 221–226 (2012).
33.
KommB. A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod. Sci.15(10), 984–992 (2008).
34.
Premarin®, package insert. Pfizer, NY, USA.
35.
KharodeYBodinePVMillerCPLyttleCRKommBS. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology149(12), 6084–6091 (2008).
36.
Review of preclinical data on conjugated estrogen/bazedoxifene.
37.
LoboRAPinkertonJVGassMLEvaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil. Steril.92(3), 1025–1038 (2009).
38.
Primary SMART-1 publication.
39.
PinkertonJVUtianWHConstantineGDOlivierSPickarJH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause16(6), 1116–1124 (2009).
40.
Primary SMART-2 publication.
41.
KaganRWilliamsRSPanKMirkinSPickarJH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause17(2), 281–289 (2010).
42.
Primary SMART-3 publication.
43.
PinkertonJVTaylorHPanKChinesAMirkinS. Breast parameters with bazedoxifene/conjugated estrogens in randomized, controlled trials of postmenopausal women. Menopause17(6), 1221–1222 (2010).
44.
Primary SMART-5 publication.
45.
YuHRacketaJChinesAAMirkinS. Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women. Climacteric16(2), 252–257 (2013).
46.
UtianWYuHBobulaJMirkinSOlivierSPickarJH. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas63(4), 329–335 (2009).
47.
PinkertonJVPanKAbrahamLSleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: a randomized trial. Menopause doi:10.1097/GME.0b013e31829f0433 (2013) (Epub ahead of print).
48.
PinkertonJVHarveyJAPanKBreast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. Obstet. Gynecol.121(5), 959–968 (2013).
49.
Primary presentation on breast safety data from SMART-5.
50.
MirkinSKommBS. Tissue-selective estrogen complexes for postmenopausal women. Maturitas76(3), 213–220 (2013).
51.
Comprehensive review on the development of conjugated estrogen/bazedoxifene.
52.
AndersonGLLimacherMAssafAR; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA291(14), 1701–1712 (2004).
53.
AndersonGLChlebowskiRTAragakiAKConjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol.13(7), 476–486 (2012).
54.
KommBSLyttleCR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann. NY Acad. Sci.949, 317–326 (2001).
55.
WardellSENelsonERChaoCAMcDonnellDP. Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. Clin. Cancer Res.19(9), 2420–2431 (2013).
56.
PinkertonJVArcherDFUtianWHBazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause16(6), 1102–1108 (2009).
57.
ArcherDFPinkertonJVUtianWHBazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause16(6), 1109–1115 (2009).
58.
ChristiansenCChesnutCH3rdAdachiJDSafety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet. Disord.11, 130 (2010).
59.
HarveyJAHolmMKRanganathRGusePATrottEAHelznerE. The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis. Menopause16(6), 1193–1196 (2009).
60.
HarveyJAPinkertonJVBaracatECShiHChinesAAMirkinS. Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens. Menopause20(2), 138–145 (2013).
61.
Primary presentation on breast safety data of conjugated estrogen/bazedoxifene in SMART-1.
62.
MansonJEChlebowskiRTStefanickMLMenopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA310(13), 1353–1368 (2013).
63.
LoboRABushTCarrBRPickarJH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil. Steril.76(1), 13–24 (2001).
64.
StovallDWUtianWHGassMLThe effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause14(3), 510–517 (2007).
